Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 9,377 matching trials from the live ClinicalTrials.gov search.

Filters: Portland, Oregon Clear all

Conditions: Low-grade Glioma
Interventions: DAY101; Drug
Lead sponsor: Karen D. Wright, MD; Other
Eligibility: 1 Year to 25 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 15
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 10 more

Conditions: Melanoma (Skin)
Interventions: aldesleukin, filgrastim, recombinant interferon alfa, cisplatin, dacarbazine, vinblastine; Biological · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 482 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 94
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more

Conditions: Non-Infectious Uveitis
Interventions: FAI insert, Sham injection; Drug
Lead sponsor: EyePoint Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 16
States / cities: Beverly Hills, California • Sacramento, California • Torrance, California + 13 more

Conditions: Episodic Migraine
Interventions: Standard of Care (SOC) Migraine Preventive Medication, Atogepant; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 744 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 112
States / cities: Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 100 more

Conditions: Diabetic Macular Edema (DME)
Interventions: Remigromig, Ranibizumab; Drug
Lead sponsor: EyeBiotech Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 1,054 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 107
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 96 more

Conditions: Persistent Asthma
Interventions: Beclomethasone dipropionate breath-actuated inhaler, Placebo breath-actuated inhaler, albuterol/salbutamol; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 47
States / cities: Huntington Beach, California • Mission Viejo, California • Orange, California + 41 more

Conditions: Dermatitis, Dermatitis, Atopic, Eczema, Skin Diseases, Skin Diseases, Genetic, Genetic Diseases, Inborn, Skin Diseases, Eczematous, Hypersensitivity, Hypersensitivity, Immediate, Immune System Diseases
Interventions: PF-04965842 100 mg, PF-04965842 200 mg, Dupilumab, Oral Placebo, Injectable Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 838 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 60
States / cities: Birmingham, Alabama • Huntington Beach, California • Laguna Hills, California + 52 more

Conditions: PIK3CA-related Overgrowth Spectrum (PROS)
Interventions: Alpelisib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 100 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 11
States / cities: Sacramento, California • Washington D.C., District of Columbia • St Louis, Missouri + 7 more

Conditions: Alopecia Areata
Interventions: JNJ-64304500, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 9
States / cities: Tampa, Florida • Plainfield, Indiana • Louisville, Kentucky + 5 more

Conditions: Acute Coronary Syndrome
Interventions: Apixaban, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 7,484 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 221
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 179 more

Conditions: Influenza, Human
Interventions: Quadrivalent influenza modRNA vaccine, Quadrivalent influenza vaccine; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 45,789 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 263
States / cities: Athens, Alabama • Birmingham, Alabama • Dothan, Alabama + 192 more

Conditions: Cystic Fibrosis
Interventions: azithromycin, placebo, Tobramycin solution for inhalation; Drug
Lead sponsor: Bonnie Ramsey; Other
Eligibility: 6 Months to 18 Years
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 45
States / cities: Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 40 more

Conditions: Onychomycosis of Toenail
Interventions: Hallux Terbinafine Subungual Gel; Drug
Lead sponsor: Hallux, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Mesa, Arizona • Parker, Colorado • Portland, Oregon + 1 more

Conditions: Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Interventions: capecitabine, gemcitabine hydrochloride; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 112
States / cities: Mobile, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 79 more

Conditions: Parkinson Disease, GBA Gene Mutation, Gaucher Disease
Interventions: PET scan, neuroQWERTY; Diagnostic Test
Lead sponsor: Pacific Parkinson's Research Centre; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 2
States / cities: Portland, Oregon • Seattle, Washington

Conditions: Pulmonary Hypertension, Pulmonary Fibrosis
Interventions: Oral treprostinil; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 79 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 7
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 4 more

Conditions: Carotid Artery Diseases
Interventions: Transcarotid Artery Revascularization (TCAR); Procedure
Lead sponsor: Silk Road Medical; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 53
States / cities: Huntsville, Alabama • Scottsdale, Arizona • Tucson, Arizona + 49 more

Conditions: Vesicoureteral Reflux, Urinary Tract Infections
Interventions: Trimethoprim-Sulfamethoxazole, Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 2 Months to 71 Months
Enrollment: 607 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 19
States / cities: Birmingham, Alabama • Wilmington, Delaware • Washington D.C., District of Columbia + 16 more

Conditions: Migraine
Interventions: BHV-3500 (zavegepant), Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,753 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 116
States / cities: Phoenix, Arizona • Tucson, Arizona • Canoga Park, California + 88 more

Conditions: Carcinoma, Renal Cell
Interventions: axitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 31
States / cities: Antioch, California • Bakersfield, California • Pleasant Hill, California + 17 more

Conditions: Lung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma Bladder
Interventions: IO102-IO103 in combination with pembrolizumab; Drug
Lead sponsor: IO Biotech; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 9
States / cities: Duarte, California • Sacramento, California • San Diego, California + 6 more

Conditions: Cystic Fibrosis, Pancreatic Insufficiency
Interventions: Liprotamase, Placebo; Drug
Lead sponsor: Anthera Pharmaceuticals; Industry
Eligibility: 7 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 27
States / cities: Birmingham, Alabama • Palo Alto, California • Denver, Colorado + 23 more

Conditions: Cystic Fibrosis
Interventions: Ivacaftor, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 39
States / cities: Birmingham, Alabama • Oakland, California • Palo Alto, California + 34 more

Conditions: Alzheimer's Disease
Interventions: Semorinemab, Placebo, [18F]GTP1; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 457 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 43
States / cities: Birmingham, Alabama • Glendale, California • Irvine, California + 39 more

Search by objective public record fields.

DAY101 In Gliomas and Other Tumors

Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma

Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert

Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine

A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME

A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma

Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)

A Study of JNJ-64304500 in Participants With Alopecia Areata

Phase III Acute Coronary Syndrome

A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older

OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis

To Evaluate Hallux Terbinafine Subungual Gel (HSG) in the Treatment of Onychomycosis

S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma

The GBA Multimodal Study in Parkinson's Disease

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

Post-approval Study of Transcarotid Artery Revascularization in Standard Risk Patients With Significant Carotid Artery Disease

Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR)

A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer

IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC

Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation

A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease